Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

A Novel Partial MHC Class II Construct, DRmQ, Inhibits Central and Peripheral Inflammatory Responses to Promote Neuroprotection in Experimental Stroke.

Lee JY, Castelli V, Bonsack B, Coats AB, Navarro-Torres L, Garcia-Sanchez J, Kingsbury C, Nguyen H, Vandenbark AA, Meza-Romero R, Offner H, Borlongan CV.

Transl Stroke Res. 2019 Dec 3. doi: 10.1007/s12975-019-00756-1. [Epub ahead of print]

PMID:
31797249
2.

Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE.

Seifert HA, Gerstner G, Kent G, Vandenbark AA, Offner H.

J Neuroinflammation. 2019 Oct 29;16(1):195. doi: 10.1186/s12974-019-1588-z.

3.

Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke.

Seifert HA, Zhu W, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2019 Dec;34(6):1705-1712. doi: 10.1007/s11011-019-00476-3. Epub 2019 Aug 13.

4.

A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.

Vandenbark AA, Meza-Romero R, Benedek G, Offner H.

J Neuroinflammation. 2019 Jan 23;16(1):14. doi: 10.1186/s12974-018-1393-0. Review.

5.

Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.

Meza-Romero R, Benedek G, Gerstner G, Kent G, Nguyen H, Offner H, Vandenbark AA.

Metab Brain Dis. 2019 Feb;34(1):153-164. doi: 10.1007/s11011-018-0331-2. Epub 2018 Oct 23.

6.

The splenic response to stroke: from rodents to stroke subjects.

Seifert HA, Offner H.

J Neuroinflammation. 2018 Jul 3;15(1):195. doi: 10.1186/s12974-018-1239-9. Review.

7.

Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells.

Seifert HA, Benedek G, Nguyen H, Gerstner G, Zhang Y, Kent G, Vandenbark AA, Bernhagen J, Offner H.

Metab Brain Dis. 2018 Oct;33(5):1599-1607. doi: 10.1007/s11011-018-0266-7. Epub 2018 Jun 18.

8.

Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical.

Bix GJ, Fraser JF, Mack WJ, Carmichael ST, Perez-Pinzon M, Offner H, Sansing L, Bosetti F, Ayata C, Pennypacker KR.

Transl Stroke Res. 2018 Jun;9(3):258-266. doi: 10.1007/s12975-018-0628-9. Epub 2018 Apr 10.

9.

Regulatory B cells in experimental stroke.

Seifert HA, Vandenbark AA, Offner H.

Immunology. 2018 Jun;154(2):169-177. doi: 10.1111/imm.12887. Epub 2018 Feb 5. Review.

10.

MIF and D-DT are potential disease severity modifiers in male MS subjects.

Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, Du X, Sreih A, Leng L, Wiedrick J, Caillier SJ, Offner H, Oksenberg JR, Yadav V, Bourdette D, Bucala R, Vandenbark AA.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.

11.

Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.

Benedek G, Zhang J, Nguyen H, Kent G, Seifert HA, Davin S, Stauffer P, Vandenbark AA, Karstens L, Asquith M, Offner H.

J Neuroimmunol. 2017 Sep 15;310:51-59. doi: 10.1016/j.jneuroim.2017.06.007. Epub 2017 Jun 21.

12.

Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen.

Seifert HA, Benedek G, Nguyen H, Kent G, Vandenbark AA, Offner H.

Metab Brain Dis. 2017 Oct;32(5):1747-1754. doi: 10.1007/s11011-017-0063-8. Epub 2017 Jul 8.

13.

Sex differences in regulatory cells in experimental stroke.

Seifert HA, Benedek G, Liang J, Nguyen H, Kent G, Vandenbark AA, Saugstad JA, Offner H.

Cell Immunol. 2017 Aug;318:49-54. doi: 10.1016/j.cellimm.2017.06.003. Epub 2017 Jun 8.

14.

Sex-dependent treatment of chronic EAE with partial MHC class II constructs.

Benedek G, Chaudhary P, Meza-Romero R, Calkins E, Kent G, Offner H, Bourdette D, Vandenbark AA.

J Neuroinflammation. 2017 May 6;14(1):100. doi: 10.1186/s12974-017-0873-y.

15.

Stroke and other cerebrovascular diseases.

Offner H, Ihara M, Schäbitz WR, Wong PT.

Neurochem Int. 2017 Jul;107:1-3. doi: 10.1016/j.neuint.2017.04.003. Epub 2017 Apr 6.

PMID:
28392459
16.

DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.

Yang L, Liu Z, Ren H, Zhang L, Gao S, Ren L, Chai Z, Meza-Romero R, Benedek G, Vandenbark AA, Offner H, Li M.

Metab Brain Dis. 2017 Oct;32(5):1395-1402. doi: 10.1007/s11011-017-9991-6. Epub 2017 Mar 16.

17.

Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.

Benedek G, Zhang J, Nguyen H, Kent G, Seifert H, Vandenbark AA, Offner H.

J Neuroimmunol. 2017 Apr 15;305:59-67. doi: 10.1016/j.jneuroim.2016.12.018. Epub 2017 Jan 28.

18.

DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.

Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, Liu H, Meza-Romero R, Vandenbark AA, Offner H, Gao Y.

Transl Stroke Res. 2017 Jun;8(3):284-293. doi: 10.1007/s12975-016-0514-2. Epub 2016 Dec 17.

19.

Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.

Yang L, Kong Y, Ren H, Li M, Wei CJ, Shi E, Jin WN, Hao J, Vandenbark AA, Offner H.

Neurochem Int. 2017 Jul;107:148-155. doi: 10.1016/j.neuint.2016.11.007. Epub 2016 Nov 21.

20.

Sex differences in the immune response to experimental stroke: Implications for translational research.

Dotson AL, Offner H.

J Neurosci Res. 2017 Jan 2;95(1-2):437-446. doi: 10.1002/jnr.23784. Review.

21.

Partial MHC class II constructs as novel immunomodulatory therapy for stroke.

Benedek G, Vandenbark AA, Alkayed NJ, Offner H.

Neurochem Int. 2017 Jul;107:138-147. doi: 10.1016/j.neuint.2016.10.007. Epub 2016 Oct 31. Review.

22.

Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis.

Benedek G, Zhang J, Bodhankar S, Nguyen H, Kent G, Jordan K, Manning D, Vandenbark AA, Offner H.

J Neuroimmunol. 2016 Apr 15;293:45-53. doi: 10.1016/j.jneuroim.2016.02.009. Epub 2016 Feb 13.

23.

Loss of PPARα perpetuates sex differences in stroke reflected by peripheral immune mechanisms.

Dotson AL, Wang J, Liang J, Nguyen H, Manning D, Saugstad JA, Offner H.

Metab Brain Dis. 2016 Jun;31(3):683-92. doi: 10.1007/s11011-016-9805-2. Epub 2016 Feb 12.

24.

Adoptive transfer of immune subsets prior to MCAO does not exacerbate stroke outcome in splenectomized mice.

Wang J, Dotson AL, Murphy SJ, Offner H, Saugstad JA.

J Syst Integr Neurosci. 2015;1(1):20-28. Epub 2015 Sep 28.

25.

Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion.

Dotson AL, Chen Y, Zhu W, Libal N, Alkayed NJ, Offner H.

Transl Stroke Res. 2016 Feb;7(1):70-8. doi: 10.1007/s12975-015-0436-4. Epub 2015 Dec 1.

26.

Sex differences and the role of PPAR alpha in experimental stroke.

Dotson AL, Wang J, Chen Y, Manning D, Nguyen H, Saugstad JA, Offner H.

Metab Brain Dis. 2016 Jun;31(3):539-47. doi: 10.1007/s11011-015-9766-x. Epub 2015 Nov 18.

27.

A novel mouse model of thromboembolic stroke.

Chen Y, Zhu W, Zhang W, Libal N, Murphy SJ, Offner H, Alkayed NJ.

J Neurosci Methods. 2015 Dec 30;256:203-11. doi: 10.1016/j.jneumeth.2015.09.013. Epub 2015 Sep 18. Review.

28.

PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.

Bodhankar S, Chen Y, Lapato A, Dotson AL, Wang J, Vandenbark AA, Saugstad JA, Offner H.

Stroke. 2015 Oct;46(10):2926-34. doi: 10.1161/STROKEAHA.115.010592. Epub 2015 Aug 25.

29.

Role for microglia in sex differences after ischemic stroke: importance of M2.

Bodhankar S, Lapato A, Chen Y, Vandenbark AA, Saugstad JA, Offner H.

Metab Brain Dis. 2015 Dec;30(6):1515-29. doi: 10.1007/s11011-015-9714-9. Epub 2015 Aug 6.

30.

IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice.

Zhang J, Benedek G, Bodhankar S, Lapato A, Vandenbark AA, Offner H.

J Neuroimmunol. 2015 Aug 15;285:129-36. doi: 10.1016/j.jneuroim.2015.06.002. Epub 2015 Jun 11.

31.

HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.

Benedek G, Meza-Romero R, Jordan K, Keenlyside L, Offner H, Vandenbark AA.

J Neuroinflammation. 2015 Jun 24;12:123. doi: 10.1186/s12974-015-0342-4.

32.

Functional role of regulatory lymphocytes in stroke: facts and controversies.

Liesz A, Hu X, Kleinschnitz C, Offner H.

Stroke. 2015 May;46(5):1422-30. doi: 10.1161/STROKEAHA.114.008608. Epub 2015 Mar 19. Review. No abstract available.

33.

Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice.

Zhang J, Lapato A, Bodhankar S, Vandenbark AA, Offner H.

Metab Brain Dis. 2015 Oct;30(5):1117-27. doi: 10.1007/s11011-015-9661-5. Epub 2015 Mar 18.

34.

Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice.

Zhu W, Dotson AL, Libal NL, Lapato AS, Bodhankar S, Offner H, Alkayed NJ.

Neuroscience. 2015 Mar 12;288:112-9. doi: 10.1016/j.neuroscience.2014.12.037. Epub 2014 Dec 31.

35.

Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells.

Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Saugstad JA, Offner H.

Metab Brain Dis. 2015 Aug;30(4):911-924. doi: 10.1007/s11011-014-9639-8. Epub 2014 Dec 25.

36.

The role of the spleen in ischemic stroke.

Pennypacker KR, Offner H.

J Cereb Blood Flow Metab. 2015 Feb;35(2):186-7. doi: 10.1038/jcbfm.2014.212. Epub 2014 Dec 3. Review.

37.

Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke.

Dotson AL, Wang J, Saugstad J, Murphy SJ, Offner H.

J Neuroimmunol. 2015 Jan 15;278:289-98. doi: 10.1016/j.jneuroim.2014.11.020. Epub 2014 Nov 26.

38.

Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.

Dotson AL, Zhu W, Libal N, Alkayed NJ, Offner H.

Front Cell Neurosci. 2014 Sep 25;8:284. doi: 10.3389/fncel.2014.00284. eCollection 2014.

39.

Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke.

Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, Alkayed NJ.

Transl Stroke Res. 2015 Feb;6(1):60-8. doi: 10.1007/s12975-014-0373-7. Epub 2014 Oct 2.

40.

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.

Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Offner H.

Front Cell Neurosci. 2014 Aug 11;8:228. doi: 10.3389/fncel.2014.00228. eCollection 2014.

41.

Modeling immunity and inflammation in stroke: don't be afraid of mice?

Offner H.

Stroke. 2014 Sep;45(9):e181-2. doi: 10.1161/STROKEAHA.114.005642. Epub 2014 Jul 24. No abstract available.

42.

Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ.

Transl Stroke Res. 2014 Oct;5(5):612-7. doi: 10.1007/s12975-014-0348-8. Epub 2014 Jun 24.

43.

Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke.

Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, Offner H, Hurn PD.

Transl Stroke Res. 2014 Oct;5(5):577-85. doi: 10.1007/s12975-014-0345-y. Epub 2014 May 18.

44.

Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.

Verbout NG, Yu X, Healy LD, Phillips KG, Tucker EI, Gruber A, McCarty OJ, Offner H.

Metab Brain Dis. 2015 Feb;30(1):57-65. doi: 10.1007/s11011-014-9558-8. Epub 2014 May 9.

45.

HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA.

J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28.

46.

Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H.

Metab Brain Dis. 2014 Mar;29(1):59-73. doi: 10.1007/s11011-013-9474-3. Epub 2013 Dec 28.

47.

Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice.

Banerjee A, Wang J, Bodhankar S, Vandenbark AA, Murphy SJ, Offner H.

Transl Stroke Res. 2013 Oct;4(5):554-63.

48.

A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2014 Mar;29(1):37-45. Erratum in: Metab Brain Dis. 2014 Sep;29(3):885.

49.

PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H.

J Neuroinflammation. 2013 Sep 9;10:111. doi: 10.1186/1742-2094-10-111.

50.

PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE.

Bodhankar S, Galipeau D, Vandenbark AA, Offner H.

J Clin Cell Immunol. 2013 May 6;4(3):143.

Supplemental Content

Loading ...
Support Center